Session » Systemic Sclerosis and Related Disorders – Clinical Poster III
-
Abstract Number: 2687
Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
-
Abstract Number: 2688
Increased Serum Uric Acid Levels Are Associated with a Higher Risk of Digital Ulcers in Patients with Systemic Sclerosis
-
Abstract Number: 2689
Association between Small Vessel Disease and Arterial Stiffness in Systemic Sclerosis
-
Abstract Number: 2690
Potential Markers of Skin Involvement in Systemic Sclerosis
-
Abstract Number: 2691
Increased Plasma Angiopoietin-2 in Systemic Sclerosis: Potential for Use As a Biomarker of Vasculopathy and Fibrosis
-
Abstract Number: 2692
High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis
-
Abstract Number: 2693
What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study
-
Abstract Number: 2694
Performance of Anti-Scl-70 Antibody Testing By Multiple-Bead, Enzyme-Linked Immunosorbent Assay, and Immunodiffusion in a University Setting
-
Abstract Number: 2695
Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry
-
Abstract Number: 2696
Increased Mortality in Black and Asian Patients with Systemic Sclerosis in Northern California
-
Abstract Number: 2697
Elevated Serum Interleukin-34 Levels Are Correlated with Interstitial Lung Disease in Systemic Sclerosis
-
Abstract Number: 2698
Renal Involvement in Mixed Connective Tissue Disease: A Single Center Experience
-
Abstract Number: 2699
Using ICD-10 Codes to Identify Patients with Systemic Sclerosis in the Electronic Health Record
-
Abstract Number: 2700
Rescuing Standard Analyses of Immunosuppresive Rescue Therapy in Randomized Controlled Trials: Alternative Approaches in a Scleroderma Clinical Trial
-
Abstract Number: 2701
Botulinum Toxin in the Management of Raynaud’s Phenomenon
-
Abstract Number: 2703
Delay in Initiation of Therapy Predicts Worse Outcomes in Scleroderma Renal Crisis
-
Abstract Number: 2704
Pregnancy in Systemic Sclerosis (SSc): A Systematic Review and Meta-Analysis
-
Abstract Number: 2705
Optimized Protocol for Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
-
Abstract Number: 2706
Discriminant Validity and Reliability of World Scleroderma Foundation (WSF) Definition of Skin Ulcers in Systemic Sclerosis
-
Abstract Number: 2707
Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome
-
Abstract Number: 2708
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
-
Abstract Number: 2709
Conversion of Normal Mean Pulmonary Arterial Pressure to Pulmonary Hypertension in Systemic Sclerosis – a Longitudinal Observational Study
-
Abstract Number: 2710
Physical Activity Trackers Work Well As a Monitor of Physical Activity in Systemic Sclerosis
-
Abstract Number: 2711
Comparison of Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis with That Associated with Other Diseases: Are There Differences?
-
Abstract Number: 2712
Evaluation of Longitudinal Outcomes in Scleroderma Patients with Negative Immunofluorescent Anti-Nuclear Antibodies
-
Abstract Number: 2713
Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?
-
Abstract Number: 2714
Significance of Anti-Neutrophil Cytoplasmic Antibodies in Systemic Sclerosis